The evaluation of combined scintimammography and tumor markers in breast cancer patients

Anticancer Research

Volumn 17, Issue 3 B, 1997, Pages 1611-1614

  Mangkharak, Jiraporn ^a   Patanachak, Chaweewan ^a   Podhisuwan, Krit ^a   Pleehachinda, Rudee ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Breast cancer; Scintimammography; Tumor markers

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TUMOR MARKER;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BLOOD LEVEL; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; DRUG UPTAKE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAMMOGRAPHY; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SCINTIGRAPHY;

ADULT; AGED; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; LYMPHATIC METASTASIS; MAMMOGRAPHY; MIDDLE AGED; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; RECURRENCE; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M SESTAMIBI; THALLIUM RADIOISOTOPES;

EID: 0030948922     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Moskowitz M, Gartside PS: Evidence of breast cancer mortality reduction: aggressive screening in women under age 30. AJR 138: 911-916, 1982.
2. Habbema JDF, van Oortmarssen GV, van Putten DJ et al: Age-specific reduction in breast cancer mortality by screen: an analysis of the results of Health Insurance Plan of greater New York study. JNCI 77: 317-320, 1986.
3. Homer MJ: Nonpalpable breast abnormalities: a realistic view of the accuracy of mammography in detecting malignancies. Radiology 153: 831-832, 1984.
4. Sickles EA: Mammographic features of 300 consecutive nonpalpable breast cancers. Am J Radiol 146: 661-663, 1986.
5. Pollei SR, Mettler FA, Bartow SA, et al: Occult breast cancer: prevalence and radiographic detectability. Radiology 163: 459-462, 1987.
6. Pera A, Freimanis AK: The choice of radiologic procedures in the diagnosis of breast diseases. Obstetrics and Gynecology Clinics of North Am 14(3): 635-650, 1987.
7. Moskowitz M: The predictive value of certain mammographic signs in screening for breast cancer. Cancer 51: 1007-1011, 1983.
8. Sickles EA: Breast calcifications: mammographic evaluation. Radiology 160: 289-293, 1986.
9. Mann BD, Giuliano AE, Basset LW, et al: Delayed diagnosis of breast cancer as a result of normal mammograms. Arch Surg 118: 23-25, 1983.
10. Feig SA: The role of ultrasound in breast imaging center. Sem US CT MR 10: 90-105, 1989.
11. Jackson VP: Sonography of malignant breast disease. Sem US CT MR 10(2): 119-131, 1989.
12. Jackson VP: The role of US in breast imaging. Radiology 177: 305-311, 1990.
13. Goldberg PA, White CS, McAvoy MA, Templeton PA: CT appearance of the normal and abnormal breast with mammographic correlation. Clinical imaging 18(4): 262-272, 1994.
14. Bohm-Velez M, Mendelson EB: Computed tomography: duplex doppler ultrasound and magnetic resonance imaging in evaluating the breast. Radiology 118: 425-428, 1976.
15. Serafini AN, Raskin MM, Zand LC, Watson DD: Radionuclide breast scanning in carcinoma of the breast. J Nucl Med 15: 1149-1152, 1974.
16. Strauss LG, Conti PS: The applications of PET in clinical oncology. J Nucl Med 32: 623-648, 1991.
17. Lee VW, Sax EJ, McAneny DB, et al: A complementary role for thallium-201 scintigraphy with mammography in the diagnosis of breast cancer. J Nucl Med 34: 2095-2100, 1993.
18. Waxman AD, Ramanna L, Memsic LD. et al: Thallium scintigraphy in the evaluation of mass abnonnalities of the breast. J Nucl Med 34: 18-23, 1993.
19. Khalkhali I, Mena I, Diggles L: Review of imaging techniques for the diagnosis of breast cancer: a new role of prone scintimammography using technetium-99m sestamibi. Eur J Nucl Med 21: 357-362, 1994.
20. Burak Z, Argon M, Memis A, et al: Evaluation of palpable breast masses with Tc -MIBI: a comparative study with mammography and ultrasonography. Nucl Med Comm 15: 604-612, 1994.
21. American Joint Committee on Cancer: Manual for staging of cancer. 4th ed. Philadelphia. J.B. Lippincott 1992, pp 149-154.
22. Lorcan A, O' Tuama LA, Treves ST, et al: Thallium-201 versus technetium99m-MIBI SPECT evaluation of childhood brain tumors: a within-subject comparison. J Nucl Med. 34: 1045-1051, 1993.
23. Macapinlac H, Scott A, Caluser C et al: Comparison of Tl-201 and Tc-99m MIBI with MRI in the evaluation of recurrent brain tumors. J Nucl Med 33: 867P, 1992
24. Caluser CI, Macapinlac H, Scott AM, et al: Thallium and Tc-99m MIBI imagingin evaluation of sarcomas. Eur J Nucl Med 19: 706, 1992.
25. Scopinaro F, Schillaci O, Scarpini M, et al: Technetium-99m sestamibi: an indicator of breast cancer invasiveness. Eur J Nucl Med 21: 984-987, 1994.
26. Mangkharak J, Podhisuwan K, Pleehachinda: Role of scintimammography (SMM) in the diagnosis and prognostic outcome of primary breast cancer. Kaku Igaku 32: 888 (Abs), 1995.
27. Hayes DF, Zurawski VR, Jr, and Kufe DF: Comparison of circulating CA15-3 and Carcinoembryonic antigen levels in patients with breast cancer. J Clin One 4 (10): 1542-1550, 1986.
28. Dnistrian AM, Schwartz M, Greenberg EJ, et al: CA15-3 and carcinocmbryonic antigen in the clinical evaluation of breast cancer. Clinica Chimica Acta 200: 81-94, 1991
29. Safi F, Kohler I, Rottinger E, and Beger H: The value of the tumor marker CA15-3 in diagnosing and monitoring breast cancer: a comparative study with carcmoembryonic antigen. Cancer 68: 574-582, 1991.
30. Gion M, Mione R, Nascimben O, et al: The tumour associated antigen CA15.3 in primary breast cancer: evaluation of 667 cases. Br J Cancer 63: 809-813, 1991.
31. Geraghty JG, Coventry EC, Sherry F, et al: CA15-3 in patients with locoregional and metastatic breast carcinoma. Cancer 70: 2831-2834, 1992.
32. Kiang DT, Greenberg LJ, Kennedy BJ: Tumor marker kinetics in monitoring of breast cancer, Cancer 65: 193-199, 1990